We get a mention in yet another Fools article.I could do without these kinds of mentions.This is another of these reason to buy article followed by a reason to sell article.Even though these aren't about MannKind, they did manage to get a dig in.

"Data from a pivotal clinical trial for belinostat is due out in the fourth quarter. Spectrum is more insulated than a drug developer like MannKind (NAS: MNKD) , which will crash and burn if its lead product doesn't pass upcoming clinical trials, but Spectrum is nowhere near the level of a big pharma that can just shake off a phase 3 trial failure."

http://www.dailyfinance.com/2012/07/31/3-reasons-to-sell-spectrum-pharmaceuticals/